Sensitivity analyses on mechanical ventilation costs and discount rates did not change the interpretation of results (table 5, figure 1).
Similar patterns could be observed for mechanical ventilation and cost of hospitalization.
Outcomes of interest were in-hospital mortality, development of acute respiratory distress syndrome (ARDS), days on mechanical ventilation, hospital cost, and length of stay.
Outcomes measured included inhospital mortality, development of acute respiratory distress syndrome (ARDS), days on mechanical ventilation, hospital cost, and length of stay.
Introduction: With a high prevalence in Intensive Care Units (ICU), the Ventilator-Associated pneumonia (VAP) has been responsible for increased mortality and morbidity rates, hospital stay, duration of mechanical ventilation (MV), costs and a set of other complications.
Overall, studies showed that improvements in sedation practice, such as the introduction of guidelines and protocols, or daily interruption of sedation, were associated with improvements in outcomes including ICU and hospital length of stay, duration of mechanical ventilation, and costs.
We compared rates of VAP, days on mechanical ventilation (MV), and cost of antimicrobial agents before and during implementation.
The asynchrony during mechanical ventilation increases the cost of care, length of days on mechanical ventilation, and other morbidities associated with increased ICU stay.
The daily screening of the respiratory function followed by SBTs in selected patients can reduce the time of mechanical ventilation and the cost of intensive care, besides being associated with fewer complications [ 5].
Limited studies report increased mortality and ICU stay, requirement for mechanical ventilation and higher costs in ventilator-associated Tracheobronchitis (TAV) in comparison to patients with ventilator-associated pneumonia (NAV).
